Patents by Inventor Xiaofang Wang

Xiaofang Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210318521
    Abstract: The present disclosure discloses an optical imaging lens assembly including, sequentially from an object side to an image side along an optical axis, a first lens having negative refractive power; a second lens having refractive power; a third lens; a fourth lens having refractive power, a convex image-side surface and a concave image-side surface; a fifth lens having refractive power and a concave object-side surface; a sixth lens; and a seventh lens. Half of a diagonal length ImgH of an effective pixel area on an imaging plane of the optical imaging lens assembly satisfies: ImgH?5.20 mm.
    Type: Application
    Filed: March 11, 2021
    Publication date: October 14, 2021
    Inventors: Xiaofang Wang, Kaiyuan Zhang, Fujian Dai, Liefeng Zhao
  • Publication number: 20210263285
    Abstract: The disclosure provides an optical imaging system, sequentially including a first lens, a second lens, a third lens, a fourth lens, a fifth lens, a sixth lens, a seventh lens and an eighth lens from an object side to an image side along an optical axis, wherein an image-side surface of the seventh lens is a concave surface; the optical imaging system meets the following conditional expressions: TTL/ImgH<1.3, f/EPD<1.8, ImgH>6 mm and 0<R15/f8<0.8, wherein TTL is a distance from an object-side surface of the first lens to an imaging surface of the optical imaging system on the optical axis; ImgH is a half of diagonal length of an effective pixel region on the imaging surface; f is a total effective focal length of the optical imaging system; EPD is an entrance pupil diameter of the optical imaging system.
    Type: Application
    Filed: January 20, 2021
    Publication date: August 26, 2021
    Inventors: Xiaofang WANG, Kaiyuan ZHANG, Fujian DAI, Liefeng ZHAO
  • Publication number: 20210199926
    Abstract: The present disclosure discloses an optical imaging lens assembly, sequentially from an object side to an image side along an optical axis, including: a first lens having refractive power, an object-side surface thereof is concave, and an image-side surface thereof is convex; a second lens having refractive power; a third lens having refractive power; a fourth lens having refractive power; a fifth lens having negative refractive power, and an object-side surface thereof is concave; a sixth lens having positive refractive power; and a seventh lens having refractive power. A total effective focal length f of the optical imaging lens assembly and an effective focal length f3 of the third lens may satisfy f3/f>1.49.
    Type: Application
    Filed: November 2, 2020
    Publication date: July 1, 2021
    Inventors: Wuchao Xu, Kaiyuan Zhang, Xiaofang Wang, Ying Zhou, Fujian Dai, Liefeng ZHAO
  • Publication number: 20210132340
    Abstract: The present disclosure discloses an optical imaging system, sequentially from an object side to an image side of the optical imaging system along an optical axis, including: a first lens having refractive power; a second lens having negative refractive power; a third lens having refractive power; a fourth lens having positive refractive power; a fifth lens having refractive power; a sixth lens having refractive power; and a seventh lens having refractive power, a concave object-side surface, and a concave image-side surface. Half of a diagonal length ImgH of an effective pixel area on an imaging plane of the optical imaging system may satisfy ImgH>6.0 mm. A total effective focal length f of the optical imaging system and an entrance pupil diameter EPD of the optical imaging system may satisfy f/EPD<1.9.
    Type: Application
    Filed: September 30, 2020
    Publication date: May 6, 2021
    Applicant: Zhejiang Sunny Optical Co., Ltd
    Inventors: Xiaofang WANG, Biao XU, Kaiyuan ZHANG, Fujian DAI, Liefeng ZHAO
  • Publication number: 20210109317
    Abstract: An optical imaging system includes an optical lens group including, sequentially along an optical axis from an object side to an image side, a first lens, a second lens, a third lens, and a fourth lens; a lens barrel, the optical lens group is accommodated in the lens barrel; and a plurality of spacers including at least two spacers disposed between the third lens and the fourth lens; the diameter D of the lens barrel at an end towards the object side and a maximum effective radius DT11 of an object-side surface of the first lens satisfy 2×DT11/D?0.5.
    Type: Application
    Filed: September 21, 2020
    Publication date: April 15, 2021
    Inventors: Xiaofang WANG, Guijie ZHU, Biao XU, Qi CHEN, Kaiyuan ZHANG, Fujian DAI, Liefeng ZHAO
  • Publication number: 20210085725
    Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cell and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.
    Type: Application
    Filed: October 9, 2020
    Publication date: March 25, 2021
    Inventors: Xiaofang WANG, Ren-He XU
  • Publication number: 20210063689
    Abstract: The present disclosure discloses an optical imaging lens group including, sequentially from an object side to an image side along an optical axis, a first lens having positive refractive power with a convex object-side surface; a second lens having refractive power; a third lens having refractive power; a fourth lens having refractive power; a fifth lens having refractive power; and a sixth lens having negative refractive power with a concave object-side surface and a convex image-side surface. A total effective focal length f of the optical imaging lens group, an entrance pupil diameter EPD of the optical imaging lens group and half of a maximal field-of-view Semi-FOV of the optical imaging lens group satisfy: f/EPD<2, and f*tan(Semi-FOV)>4.5 mm.
    Type: Application
    Filed: August 18, 2020
    Publication date: March 4, 2021
    Applicant: Zhejiang Sunny Optical Co., Ltd.
    Inventors: Biao XU, Kaiyuan ZHANG, Xiaofang WANG, Fujian DAI, Liefeng ZHAO
  • Publication number: 20210032196
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Inventors: Mario Rottlander, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen, Anette Graven Sams, Krestian Larsen
  • Publication number: 20200392463
    Abstract: The present invention relates to methods of generating and expanding pitman embryonic stem cell derived mesenchymal-like stem/stromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the bland-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.
    Type: Application
    Filed: January 17, 2020
    Publication date: December 17, 2020
    Inventors: Xiaofang WANG, Ren-He XU
  • Publication number: 20200368191
    Abstract: This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.
    Type: Application
    Filed: December 6, 2018
    Publication date: November 26, 2020
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Vicente E. Torres, Fouad T. Chebib, Peter C. Harris, Xiaofang Wang
  • Patent number: 10842826
    Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblast in hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically. T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: November 24, 2020
    Assignees: IMSTEM BIOTECHNOLOGY, INC., UNIVERSITY OF CONNECTICUT
    Inventors: Xiaofang Wang, Ren-He Xu
  • Publication number: 20200172474
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 4, 2020
    Inventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
  • Patent number: 10590067
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Exemplary compounds of the invention have the structure of Formula 1. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: March 17, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
  • Patent number: 10557122
    Abstract: The present invention relates to methods of generating and expanding hitman embryonic stem cell derived mesenchymal-like stem/stromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the blood-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: February 11, 2020
    Assignee: IMSTEM BIOTECHNOLOGY, INC.
    Inventors: Xiaofang Wang, Ren-He Xu
  • Patent number: 10495298
    Abstract: A water-cooled column (4) used in a circulating fluidized bed boiler furnace is disclosed, wherein the water-cooled column is formed by connecting membrane water-cooled walls (41). The water-cooled column (4) includes a lower section (A), an upper section and a transition section. The lower section (A) is a single column and is provided with inner secondary air ports (400) on a side wall thereof. The upper section includes a plurality of sub-columns (B, C). The membrane water-cooled walls at the lower section (A) extend to the upper section through the transition section. Each of the sub-columns (B, C) is formed by connecting extension portions extending upward from respective membrane water-cooled walls (41) in the membrane water-cooled walls (41), which are connected to form the lower section (A), and the plurality of sub-columns (B, C) are separated from each other.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: December 3, 2019
    Assignee: Institute of Engineering Thermophysics, Chinese Academy of Sciences
    Inventors: Qinggang Lv, Xiaofang Wang, Ming Gao, Guoliang Song, Dongyu Wang
  • Publication number: 20190256456
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Application
    Filed: February 20, 2018
    Publication date: August 22, 2019
    Inventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
  • Publication number: 20190167733
    Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblast in hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically. T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.
    Type: Application
    Filed: January 23, 2019
    Publication date: June 6, 2019
    Inventors: Xiaofang WANG, Ren-He XU
  • Patent number: 10226488
    Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: March 12, 2019
    Assignees: IMSTEM BIOTECHNOLOGY, INC., University of Connecticut
    Inventors: Xiaofang Wang, Ren-He Xu
  • Publication number: 20180010098
    Abstract: The present invention relates to methods of generating and expanding hitman embryonic stem cell derived mesenchymal-like stem/stromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the blood-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.
    Type: Application
    Filed: July 21, 2017
    Publication date: January 11, 2018
    Inventors: Xiaofang WANG, Ren-He XU
  • Publication number: 20170290864
    Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 12, 2017
    Inventors: Xiaofang WANG, Ren-He XU